General Surgical Innovations
This article was originally published in The Gray Sheet
Manufacturer of tissue dissection systems for minimally invasive surgery reports Aug. 4 that it will be allowed to recover legal fees in connection with a patent infringement suit filed by Guidant subsidiary Origin Medsystems in San Jose, California federal court. Earlier, the court found that Origin had obtained the patent through misrepresentations, according to GSI. For the fourth quarter ended June 30, GSI reported revenues of $1.3 mil., down from $2.5 mil. in the fourth quarter of fiscal 1997, and a net loss of $3 mil. versus $971,000 a year ago. For the 12 months, revenues advanced 24% to $5.2 mil., and the company's net loss increased to $9.1 mil. from $1.9 mil. in 1997
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.